HROW Logo

Harrow Health, Inc. (HROW) 

NASDAQ
Market Cap
$1.7B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
78 of 776
Rank in Industry
3 of 47

Largest Insider Buys in Sector

HROW Stock Price History Chart

HROW Stock Performance

About Harrow Health, Inc.

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and …

Insider Activity of Harrow Health, Inc.

Over the last 12 months, insiders at Harrow Health, Inc. have bought $2.21M and sold $0 worth of Harrow Health, Inc. stock.

On average, over the past 5 years, insiders at Harrow Health, Inc. have bought $2.11M and sold $267,838 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Opaleye Management Inc. (10 percent owner) — $10.22M. BAUM MARK L (Chief Executive Officer) — $330,270.

The last purchase of 20,000 shares for transaction amount of $199,400 was made by Opaleye Management Inc. (10 percent owner) on 2024‑04‑25.

List of Insider Buy and Sell Transactions, Harrow Health, Inc.

2024-04-25Purchase10 percent owner
20,000
0.0546%
$9.97$199,400+149.15%
2024-04-24Purchase10 percent owner
8,285
0.023%
$10.15$84,093+141.67%
2024-04-23Purchase10 percent owner
11,715
0.033%
$10.29$120,547+139.39%
2024-04-19Purchase10 percent owner
29,400
0.084%
$10.56$310,391+135.34%
2024-03-28Purchase10 percent owner
50,000
0.137%
$12.82$641,000+66.64%
2024-03-22PurchaseCHIEF EXECUTIVE OFFICER
9,000
0.0256%
$11.59$104,310+87.11%
2024-03-20Purchase10 percent owner
50,600
0.1322%
$9.65$488,290+102.85%
2023-11-16PurchaseChief Executive Officer
7,500
0.0201%
$8.11$60,825+42.31%
2023-11-15Purchase10 percent owner
25,000
0.0711%
$8.03$200,735+49.94%
2023-09-20Purchase10 percent owner
5,983
0.0175%
$14.49$86,710-9.65%
2023-09-19Purchase10 percent owner
14,017
0.04%
$14.65$205,366-12.55%
2023-08-14PurchaseChief Executive Officer
5,800
0.0168%
$17.05$98,890-25.74%
2023-08-14Purchasedirector
20,000
0.0576%
$16.92$338,400-25.74%
2022-12-22PurchaseChief Executive Officer
25,000
0.0941%
$13.39$334,750+26.91%
2022-12-22PurchaseChief Financial Officer
2,500
0.0095%
$13.54$33,850+26.91%
2022-12-22Purchasedirector
1,860
0.007%
$13.42$24,961+26.91%
2022-12-21Purchasedirector
25,000
0.0932%
$13.37$334,250+25.88%
2022-12-14Purchasedirector
431,183
1.3468%
$10.52$4.54M+34.06%
2022-09-30Sale
40,000
0.1586%
$12.62$504,800+42.42%
2022-04-12Purchase
3,557
0.0131%
$6.75$24,004+61.74%

Insider Historical Profitability

28.89%
Opaleye Management Inc.10 percent owner
3815000
10.7517%
$48.04290+26.89%
BAUM MARK LCHIEF EXECUTIVE OFFICER
2137525
6.0241%
$48.0450+35.4%
Singh JulietCEO, Director and President
1954125
5.5072%
$48.0420
BOLL ANDREW R.Chief Financial Officer
255063
0.7188%
$48.0420+35.4%
THORNLEY ANTHONY Sdirector
60900
0.1716%
$48.0460

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Opaleye Management Inc$51.87M11.083.92M+2.63%+$1.33M11.45
Private Capital Management LLC$39.85M8.513.01M+7.8%+$2.88M4.73
BlackRock$28.88M6.172.18M-1.7%-$499,829.39<0.01
The Vanguard Group$24.21M5.171.83M+1.18%+$281,177.19<0.0001
Morgan Stanley$12.6M2.69952,523-30.31%-$5.48M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.